‘I don't feel we lost momentum’: Takeda’s oncology execs sharpen focus after restructuring

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell therapy work focus to the backburner.